TY - JOUR
T1 - Statins use and coronary artery plaque composition
T2 - Results from the International Multicenter CONFIRM Registry
AU - Nakazato, Ryo
AU - Gransar, Heidi
AU - Berman, Daniel S.
AU - Cheng, Victor Y.
AU - Lin, Fay Y.
AU - Achenbach, Stephan
AU - Al-Mallah, Mouaz
AU - Budoff, Matthew J.
AU - Cademartiri, Filippo
AU - Callister, Tracy Q.
AU - Chang, Hyuk Jae
AU - Cury, Ricardo C.
AU - Chinnaiyan, Kavitha
AU - Chow, Benjamin J.W.
AU - Delago, Augustin
AU - Hadamitzky, Martin
AU - Hausleiter, Joerg
AU - Kaufmann, Philipp
AU - Maffei, Erica
AU - Raff, Gilbert
AU - Shaw, Leslee J.
AU - Villines, Todd C.
AU - Dunning, Allison
AU - Feuchtner, Gudrun
AU - Kim, Yong Jin
AU - Leipsic, Jonathon
AU - Min, James K.
N1 - Funding Information:
Dr. Min received modest speakers' bureau and medical advisory board compensation and significant research support from GE Healthcare. Dr. Achenbach received grant support from Siemens and Bayer Schering Pharma and has served as a consultant for Servier. Dr. Al-Mallah received support from the American Heart Association , BCBS Foundation of Michigan , and Astellas. Dr. Cademartiri received grant support from GE Healthcare and has served on the Speakers' Bureau of Bracco and as a consultant for Servier; Dr. Maffei received grant support from GE Healthcare. Dr. Chinnaiyan received grant support from Bayer Pharma and Blue Cross Blue Shield Blue Care MI . Dr. Chow received research and fellowship support from GE Healthcare, research support from Pfizer and AstraZeneca, and educational support from TeraRecon. Dr. Hausleiter received a research grant from Siemens Medical Systems . Dr. Kaufmann received institutional research support from GE Healthcare and grant support from Swiss National Science Foundation . Dr. Maffei received grant support from GE Healthcare Dr. Raff received grant support from Siemens , Blue Cross Blue Shield Blue Care MI , and Bayer Pharma . All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
PY - 2012/11
Y1 - 2012/11
N2 - Objective: The effect of statins on coronary artery plaque features beyond stenosis severity is not known. Coronary CT angiography (CCTA) is a novel non-invasive method that permits direct visualization of coronary atherosclerotic features, including plaque composition. We evaluated the association of statin use to coronary plaque composition type in patients without known coronary artery disease (CAD) undergoing CCTA. Methods: From consecutive individuals, we identified 6673 individuals (2413 on statin therapy and 4260 not on statin therapy) with no known CAD and available statin use status. We studied the relationship between statin use and the presence and extent of specific plaque composition types, which was graded as non-calcified (NCP), mixed (MP), or calcified (CP) plaque. Results: The mean age was 59 ± 11 (55% male). Compared to the individuals not taking statins, those taking statins had higher prevalence of risk factors and obstructive CAD. In multivariable analyses, statin use was associated with increased the presence of MP [odds ratio (OR) 1.46, 95% confidence interval (CI) 1.27-1.68), p < 0.001] and CP (OR 1.54, 95% CI 1.36-1.74, p < 0.001), but not NCP (OR 1.11, 95% CI 0.96-1.29, p = 0.1). Further, in multivariable analyses, statin use was associated with increasing numbers of coronary segments possessing MP (OR 1.52, 95% CI 1.34-1.73, p < 0.001) and CP (OR 1.52, 95% CI 1.36-1.70, p < 0.001), but not coronary segments with NCP (OR 1.09, 95% CI 0.94-1.25, p = 0.2). Conclusion: Statin use is associated with an increased prevalence and extent of coronary plaques possessing calcium. The longitudinal effect of statins on coronary plaque composition warrants further investigation.
AB - Objective: The effect of statins on coronary artery plaque features beyond stenosis severity is not known. Coronary CT angiography (CCTA) is a novel non-invasive method that permits direct visualization of coronary atherosclerotic features, including plaque composition. We evaluated the association of statin use to coronary plaque composition type in patients without known coronary artery disease (CAD) undergoing CCTA. Methods: From consecutive individuals, we identified 6673 individuals (2413 on statin therapy and 4260 not on statin therapy) with no known CAD and available statin use status. We studied the relationship between statin use and the presence and extent of specific plaque composition types, which was graded as non-calcified (NCP), mixed (MP), or calcified (CP) plaque. Results: The mean age was 59 ± 11 (55% male). Compared to the individuals not taking statins, those taking statins had higher prevalence of risk factors and obstructive CAD. In multivariable analyses, statin use was associated with increased the presence of MP [odds ratio (OR) 1.46, 95% confidence interval (CI) 1.27-1.68), p < 0.001] and CP (OR 1.54, 95% CI 1.36-1.74, p < 0.001), but not NCP (OR 1.11, 95% CI 0.96-1.29, p = 0.1). Further, in multivariable analyses, statin use was associated with increasing numbers of coronary segments possessing MP (OR 1.52, 95% CI 1.34-1.73, p < 0.001) and CP (OR 1.52, 95% CI 1.36-1.70, p < 0.001), but not coronary segments with NCP (OR 1.09, 95% CI 0.94-1.25, p = 0.2). Conclusion: Statin use is associated with an increased prevalence and extent of coronary plaques possessing calcium. The longitudinal effect of statins on coronary plaque composition warrants further investigation.
KW - Coronary CTA
KW - Coronary artery disease
KW - Lipid profile
KW - Plaque composition
KW - Statin
UR - http://www.scopus.com/inward/record.url?scp=84867882230&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867882230&partnerID=8YFLogxK
U2 - 10.1016/j.atherosclerosis.2012.08.002
DO - 10.1016/j.atherosclerosis.2012.08.002
M3 - Article
C2 - 22981406
AN - SCOPUS:84867882230
SN - 0021-9150
VL - 225
SP - 148
EP - 153
JO - Atherosclerosis
JF - Atherosclerosis
IS - 1
ER -